InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
+22.2%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by BAUM MARK L, Chief Executive Officer. Director active across 4 companies, notably HARROW, INC.. Aggregated, 14 reports have been logged. Breakdown: 6 buys · 0 sell. Total volume traded: €1.1m. Activity tracked since 20 January 2022. The latest transaction was disclosed on 14 May 2026 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations14 total
10,000 shares@ US$30.06090.022% mcap100.0% of flowCommon StockSEC:0001493152-26-023321
Ideal exit: 8 Feb 2027 (T+270)
10,000 shares@ US$30.200.022% mcap100.0% of flowCommon StockSEC:0001493152-26-023321:0
Ideal exit: 8 Feb 2027 (T+270)
762,300 shares0Common StockSEC:0001641172-25-003109:0
9,000 shares@ US$11.594.8% of flowCommon stockSEC:0001493152-24-011071:0
Ideal exit: 17 Dec 2024 (T+270)
150,000 shares@ US$10.6774.0% of flowCommon stockSEC:0001493152-24-007453:0
15,400 shares@ US$7.715.5% of flowCommon stockSEC:0001493152-24-005371:0
7,500 shares@ US$8.112.8% of flowCommon StockSEC:0001493152-23-041691:0
Ideal exit: 12 Aug 2024 (T+270)
5,800 shares@ US$17.054.2% of flowCommon StockSEC:0001493152-23-028832:0
Ideal exit: 10 May 2024 (T+270)
762,300 sharesCommon StockSEC:0001493152-23-025150:0
180,000 shares@ US$8.9968.9% of flowCommon StockSEC:0001493152-23-010886:0
88,000 sharesCommon StockSEC:0001493152-23-000190:0
25,000 shares@ US$13.3914.7% of flowCommon StockSEC:0001493152-22-036396:0
Ideal exit: 18 Sept 2023 (T+270)
125,000 shares@ US$2.400.023% mcap100.0% of flowCommon StockSEC:0001493152-22-002006
125,000 shares@ US$2.400.014% mcap100.0% of flowCommon StockSEC:0001493152-22-002006:0
14 of 14 declarations
About BAUM MARK L
Mark L. Baum is the CEO of Harrow, Inc. and Harrow Health, Inc. In this role, he is responsible for the strategic and operational direction of the companies. With extensive experience in the healthcare sector, he focuses on innovation and enhancing services. His leadership is essential for achieving growth objectives and strengthening the companies' market position.
